Skip to main content
Premium Trial:

Request an Annual Quote

Personalis: Woodrow Myers

Personalis has appointed Woodrow Myers to its Board of Directors as well as to the nominating and corporate governance committee of the Board. The firm simultaneously announced that Patrick Balthrop has resigned his position as a director of the company, effective March 8, 2021.

Myers is currently the managing director of Myers Ventures. He previously served as the chief medical officer and chief healthcare strategist at Blue Cross & Blue Shield of Arizona, and has held executive positions with Havencrest Healthcare Partners, Corizon Health, and Wellpoint Health Networks. He has served on multiple public, private, and nonprofit boards including those of Express Scripts, Genomic Health, LipoScience, and SynGen. His government roles including serving as physician health advisor to the United States Senate Committee on Labor and Human Resources, as Health Commissioner for his home state of Indiana, and as the Commissioner of Health for the City of New York.

Myers holds a BS in Biological Science and a medical degree from Harvard University. He is board-certified in internal medicine and has held honors including master of the American College of Physicians, member of National Academy of Medicine, and fellow of the American Association for Physician Leadership.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.